Company Profile
Enanta Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- ENTA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
13.34 USD (+0.91%)
Close
Last updated: August 6, 2026
350M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ENTA closed up 0.91% at $13.34. No new same-company headline was identified in the current news window.
Company overview
Small-Molecule Research Platform
Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment.
EDP-978 KIT Inhibitor
EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic urticaria and potentially other mast-cell-mediated diseases.
EPS-3903 STAT6 Inhibitor
EPS-3903 is an oral STAT6 inhibitor intended for atopic dermatitis and other type 2 inflammatory diseases currently treated with injectable biologics.
MRGPRX2 Discovery Program
Enanta is also developing inhibitors of MRGPRX2, a mast-cell and peripheral-neuron receptor implicated in urticaria, asthma, prurigo nodularis and migraine.
Respiratory Antiviral Program
Zelicapavir is an oral antiviral being prepared for pivotal development in high-risk adults with respiratory syncytial virus. EDP-323 provides a second RSV mechanism that may be used alone or in combination.
Future catalysts
Topline Phase 1 data for EDP-978 in the fourth quarter of 2026.
IND submission for EPS-3903 in the second half of 2026.
Recent news
- 01
- 02
- 03
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Source: Enanta Pharmaceuticals
- 04
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Source: Enanta Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
Enanta Pharmaceuticals (ENTA) most recently closed at 13.34 USD, a +0.91% move versus the previous session.
What is the market cap of Enanta Pharmaceuticals (ENTA)?
Enanta Pharmaceuticals currently has a market capitalization of 350M USD on BioPharmSignal.
What does Enanta Pharmaceuticals do?
Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic urticaria and potentially...
On which exchange is ENTA stock listed?
Enanta Pharmaceuticals (ENTA) is associated with NASDAQ, United States, Biopharma.
What is EDP-978?
Topline Phase 1 data for EDP-978 in the fourth quarter of 2026.
Which conditions is Enanta Pharmaceuticals targeting with EDP-978?
Enanta Pharmaceuticals is associated with immunology, respiratory disease based on its company overview and current catalyst commentary.
How does Enanta Pharmaceuticals describe recent progress with EDP-978?
Topline Phase 1 data for EDP-978 in the fourth quarter of 2026.
What is EPS-3903?
EPS-3903 STAT6 Inhibitor EPS-3903 is an oral STAT6 inhibitor intended for atopic dermatitis and other type 2 inflammatory diseases currently treated with injectable biologics.